Applied Evidence

COPD inhaler therapy: A path to success

Author and Disclosure Information

 

References

Patient education is necessary to ensure that drug is delivered to the patient consistently, with the same expectation of effect seen in efficacy studies (which usually provide rigorous inhaler technique training and require demonstration of proficiency).1,2,10 For the busy clinician, a multidisciplinary approach, discussed shortly, can help. Guidelines developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommend that inhaler technique be reassessed at every visit and when evaluating treatment response.1TABLE 13-9 provides information on each device type, patient requirements for use, proper technique, common errors in use, and tips for optimizing delivery.

Inhaler education and assessment of technique that is provided to patients in collaboration with a clinical pharmacist, nursing staff, and a respiratory therapist can help alleviate the pressure on a time-constrained primary care physician. Furthermore, pharmacist involvement in the COPD management team meaningfully improves inhaler technique and medication adherence.6,7 Intervention by a pharmacist correlates with a significant reduction in number of exacerbations; an increased likelihood that the patient has a COPD care plan and has received the pneumococcal vaccine; and an improvement in the mean health-related quality of life.11,12

In primary care practices that lack robust multidisciplinary resources, we recommend utilizing virtual resources, such as educational videos, to allow face-to-face or virtual education. A free source of such resources is the COPD Foundation,a a not-for-profit organization funded partly by industry.

Short- and long-acting inhaled medications for COPD

Each class of inhaled medication for treating COPD is discussed broadly in the following sections. TABLE 21 provides details about individual drugs, devices available to deliver them, and starting dosages.

Inhaled pharmacotherapeutic agents for COPD
Inhaled pharmacotherapeutic agents for COPD

Short-acting agents

These drugs are available in MDI, SMI, and nebulizer delivery devices. When portability and equipment burden are important to the patient, we recommend an MDI over a nebulizer; an MDI is as efficacious as a nebulizer in improving forced expiratory volume in 1 second (FEV1) and reducing the length of hospital stay for exacerbations.4

Continue to: SABAs

Pages

Recommended Reading

Home program improves some functional capacity in COPD
MDedge Family Medicine
Nearly 30% of U.S. cancer deaths linked to smoking
MDedge Family Medicine
Inhaled, systemic steroids linked to changes in brain structure
MDedge Family Medicine
Many young kids with COVID may show no symptoms
MDedge Family Medicine
Cannabis industry cribs Big Tobacco’s social responsibility initiatives
MDedge Family Medicine
RETHINC takes air out of COPD-like therapy for smokers
MDedge Family Medicine
Biomarker-guided steroid therapy shown safe for COPD
MDedge Family Medicine
Unvaccinated 10 times more likely to be hospitalized for Omicron
MDedge Family Medicine
New study supports safety of COVID-19 boosters during pregnancy
MDedge Family Medicine
Influenza vaccine may offer much more than flu prevention
MDedge Family Medicine